Skip header and navigation

Refine By

6 records – page 1 of 1.

The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy.

https://arctichealth.org/en/permalink/ahliterature163300
Source
Can J Cardiol. 2007 May 15;23(7):539-50
Publication Type
Conference/Meeting Material
Article
Date
May-15-2007
Author
Nadia A Khan
Brenda Hemmelgarn
Raj Padwal
Pierre Larochelle
Jeff L Mahon
Richard Z Lewanczuk
Finlay A McAlister
Simon W Rabkin
Michael D Hill
Ross D Feldman
Ernesto L Schiffrin
Norman R C Campbell
Alexander G Logan
Malcolm Arnold
Gordon Moe
Tavis S Campbell
Alain Milot
James A Stone
Charlotte Jones
Lawrence A Leiter
Richard I Ogilvie
Robert J Herman
Pavel Hamet
George Fodor
George Carruthers
Bruce Culleton
Kevin D Burns
Marcel Ruzicka
Jacques deChamplain
George Pylypchuk
Norm Gledhill
Robert Petrella
Jean-Martin Boulanger
Luc Trudeau
Robert A Hegele
Vincent Woo
Phil McFarlane
Rhian M Touyz
Sheldon W Tobe
Author Affiliation
Division of General Internal Medicine, University of British Columbia, Vancouver, British Columbia. nakhan@shaw.ca
Source
Can J Cardiol. 2007 May 15;23(7):539-50
Date
May-15-2007
Language
English
Publication Type
Conference/Meeting Material
Article
Keywords
Antihypertensive Agents - therapeutic use
Canada
Diet, Sodium-Restricted
Health promotion
Humans
Hypertension - drug therapy - prevention & control - therapy
Patient Education as Topic
Randomized Controlled Trials as Topic
Risk Reduction Behavior
Abstract
To provide updated, evidence-based recommendations for the prevention and management of hypertension in adults.
For lifestyle and pharmacological interventions, evidence was reviewed from randomized controlled trials and systematic reviews of trials. Changes in cardiovascular morbidity and mortality were the primary outcomes of interest. However, for lifestyle interventions, blood pressure lowering was accepted as a primary outcome given the lack of long-term morbidity and mortality data in this field. For treatment of patients with kidney disease, the progression of kidney dysfunction was also accepted as a clinically relevant primary outcome.
A Cochrane collaboration librarian conducted an independent MEDLINE search from 2005 to August 2006 to update the 2006 Canadian Hypertension Education Program recommendations. In addition, reference lists were scanned and experts were contacted to identify additional published studies. All relevant articles were reviewed and appraised independently by both content and methodological experts using prespecified levels of evidence.
Dietary lifestyle modifications for prevention of hypertension, in addition to a well-balanced diet, include a dietary sodium intake of less than 100 mmol/day. In hypertensive patients, the dietary sodium intake should be limited to 65 mmol/day to 100 mmol/day. Other lifestyle modifications for both normotensive and hypertensive patients include: performing 30 min to 60 min of aerobic exercise four to seven days per week; maintaining a healthy body weight (body mass index of 18.5 kg/m2 to 24.9 kg/m2) and waist circumference (less than 102 cm in men and less than 88 cm in women); limiting alcohol consumption to no more than 14 units per week in men or nine units per week in women; following a diet reduced in saturated fat and cholesterol, and one that emphasizes fruits, vegetables and low-fat dairy products, dietary and soluble fibre, whole grains and protein from plant sources; and considering stress management in selected individuals with hypertension. For the pharmacological management of hypertension, treatment thresholds and targets should take into account each individual's global atherosclerotic risk, target organ damage and any comorbid conditions: blood pressure should be lowered to lower than 140/90 mmHg in all patients and lower than 130/80 mmHg in those with diabetes mellitus or chronic kidney disease. Most patients require more than one agent to achieve these blood pressure targets. In adults without compelling indications for other agents, initial therapy should include thiazide diuretics; other agents appropriate for first-line therapy for diastolic and/or systolic hypertension include angiotensin-converting enzyme (ACE) inhibitors (except in black patients), long-acting calcium channel blockers (CCBs), angiotensin receptor blockers (ARBs) or beta-blockers (in those younger than 60 years of age). First-line therapy for isolated systolic hypertension includes long-acting dihydropyridine CCBs or ARBs. Certain comorbid conditions provide compelling indications for first-line use of other agents: in patients with angina, recent myocardial infarction, or heart failure, beta-blockers and ACE inhibitors are recommended as first-line therapy; in patients with cerebrovascular disease, an ACE inhibitor plus diuretic combination is preferred; in patients with nondiabetic chronic kidney disease, ACE inhibitors are recommended; and in patients with diabetes mellitus, ACE inhibitors or ARBs (or, in patients without albuminuria, thiazides or dihydropyridine CCBs) are appropriate first-line therapies. All hypertensive patients with dyslipidemia should be treated using the thresholds, targets and agents outlined in the Canadian Cardiovascular Society position statement (recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease). Selected high-risk patients with hypertension who do not achieve thresholds for statin therapy according to the position paper should nonetheless receive statin therapy. Once blood pressure is controlled, acetylsalicylic acid therapy should be considered.
All recommendations were graded according to strength of the evidence and voted on by the 57 members of the Canadian Hypertension Education Program Evidence-Based Recommendations Task Force. All recommendations reported here achieved at least 95% consensus. These guidelines will continue to be updated annually.
Notes
Cites: Arch Intern Med. 2000 Mar 13;160(5):685-9310724055
Cites: JAMA. 2003 Apr 23-30;289(16):2083-9312709466
Cites: N Engl J Med. 2001 Jan 4;344(1):3-1011136953
Cites: Can J Cardiol. 2001 May;17(5):543-5911381277
Cites: Ann Intern Med. 2001 Jul 17;135(2):73-8711453706
Cites: Lancet. 2004 Sep 11-17;364(9438):937-5215364185
Cites: Kidney Int Suppl. 2004 Nov;(92):S90-615485427
Cites: Hypertension. 2004 Nov;44(5):637-4215381674
Cites: Lancet. 1990 Mar 31;335(8692):765-741969518
Cites: Hypertension. 1991 Jan;17(1 Suppl):I16-201986996
Cites: JAMA. 2003 May 21;289(19):2534-4412759325
Cites: Am J Cardiol. 2003 Jun 1;91(11):1316-2212767423
Cites: J Hypertens. 2003 Jun;21(6):1055-7612777939
Cites: J Am Soc Nephrol. 2003 Jul;14(7 Suppl 2):S99-S10212819311
Cites: Can J Cardiol. 2004 Jan;20(1):41-5414968142
Cites: Can J Cardiol. 2004 Jan;20(1):55-914968143
Cites: Arch Intern Med. 2004 May 24;164(10):1084-9115159265
Cites: Lancet. 2004 Jun 19;363(9426):2022-3115207952
Cites: Cochrane Database Syst Rev. 2004;(3):CD00493715266549
Cites: Diabetes Care. 1993 Jul;16(7):996-10038359108
Cites: Diabetes Care. 1996 Jan;19(1):79-898720542
Cites: Diabetes Care. 1999 Feb;22(2):307-1310333950
Cites: Ann Intern Med. 2005 Jul 5;143(1):1-915998749
Cites: Can J Cardiol. 2005 Jun;21(8):657-7216003449
Cites: J Hypertens. 2005 Dec;23(12):2157-7216269957
Cites: JAMA. 2005 Nov 16;294(19):2455-6416287956
Cites: J Hum Hypertens. 2005 Dec;19 Suppl 3:S10-916302005
Cites: J Am Coll Cardiol. 2006 Jan 3;47(1):65-7116386666
Cites: Hypertension. 2006 Feb;47(2):296-30816434724
Cites: Am J Clin Nutr. 2006 Feb;83(2):221-616469978
Cites: Can J Cardiol. 2006 May 15;22(7):583-9316755313
Cites: Am J Clin Nutr. 2006 Jun;83(6):1289-9616762939
Cites: Ann Intern Med. 2006 Jun 20;144(12):884-9316785477
Cites: Am J Med. 2001 Nov;111(7):553-811705432
Cites: N Engl J Med. 2002 Feb 7;346(6):393-40311832527
Cites: Lancet. 2002 Mar 23;359(9311):1004-1011937179
Cites: Can J Cardiol. 2002 Jun;18(6):625-4112107420
Cites: Lancet. 2003 Jan 11;361(9352):117-2412531578
Cites: Lancet. 2003 Mar 1;361(9359):717-2512620735
Cites: Lancet. 2003 Apr 5;361(9364):1149-5812686036
Comment In: Can J Cardiol. 2007 May 15;23(7):603-417593584
PubMed ID
17534460 View in PubMed
Less detail

The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy.

https://arctichealth.org/en/permalink/ahliterature151164
Source
Can J Cardiol. 2009 May;25(5):287-98
Publication Type
Article
Date
May-2009
Author
Nadia A Khan
Brenda Hemmelgarn
Robert J Herman
Chaim M Bell
Jeff L Mahon
Lawrence A Leiter
Simon W Rabkin
Michael D Hill
Raj Padwal
Rhian M Touyz
Pierre Larochelle
Ross D Feldman
Ernesto L Schiffrin
Norman R C Campbell
Gordon Moe
Ramesh Prasad
Malcolm O Arnold
Tavis S Campbell
Alain Milot
James A Stone
Charlotte Jones
Richard I Ogilvie
Pavel Hamet
George Fodor
George Carruthers
Kevin D Burns
Marcel Ruzicka
Jacques DeChamplain
George Pylypchuk
Robert Petrella
Jean-Martin Boulanger
Luc Trudeau
Robert A Hegele
Vincent Woo
Phil McFarlane
Michel Vallée
Jonathan Howlett
Simon L Bacon
Patrice Lindsay
Richard E Gilbert
Richard Z Lewanczuk
Sheldon Tobe
Author Affiliation
Division of General Internal Medicine, University of British Columbia, Vancouver, Canada. nakhan@shaw.ca
Source
Can J Cardiol. 2009 May;25(5):287-98
Date
May-2009
Language
English
Publication Type
Article
Keywords
Adult
Aged
Antihypertensive Agents - therapeutic use
Blood Pressure Determination - standards
Canada
Case Management - standards
Combined Modality Therapy
Diet, Sodium-Restricted
Female
Health Promotion - organization & administration
Humans
Hypertension - diagnosis - therapy
Life Style
Male
Middle Aged
Patient Education as Topic
Prognosis
Program Evaluation
Randomized Controlled Trials as Topic
Treatment Outcome
Abstract
To update the evidence-based recommendations for the prevention and management of hypertension in adults for 2009.
For lifestyle and pharmacological interventions, evidence from randomized controlled trials and systematic reviews of trials was preferentially reviewed. Changes in cardiovascular morbidity and mortality were the primary outcomes of interest. However, for lifestyle interventions, blood pressure lowering was accepted as a primary outcome given the lack of long-term morbidity and mortality data in this field. Progression of kidney dysfunction was also accepted as a clinically relevant primary outcome among patients with chronic kidney disease.
A Cochrane collaboration librarian conducted an independent MEDLINE search from 2007 to August 2008 to update the 2008 recommendations. To identify additional published studies, reference lists were reviewed and experts were contacted. All relevant articles were reviewed and appraised independently by both content and methodological experts using prespecified levels of evidence.
For lifestyle modifications to prevent and treat hypertension, restrict dietary sodium to less than 2300 mg (100 mmol)/day (and 1500 mg to 2300 mg [65 mmol to 100 mmol]/day in hypertensive patients); perform 30 min to 60 min of aerobic exercise four to seven days per week; maintain a healthy body weight (body mass index 18.5 kg/m(2) to 24.9 kg/m(2)) and waist circumference (smaller than 102 cm for men and smaller than 88 cm for women); limit alcohol consumption to no more than 14 units per week in men or nine units per week in women; follow a diet that is reduced in saturated fat and cholesterol, and that emphasizes fruits, vegetables and low-fat dairy products, dietary and soluble fibre, whole grains and protein from plant sources; and consider stress management in selected individuals with hypertension. For the pharmacological management of hypertension, treatment thresholds and targets should be predicated on by the patient's global atherosclerotic risk, target organ damage and comorbid conditions. Blood pressure should be decreased to lower than 140/90 mmHg in all patients, and to lower than 130/80 mmHg in those with diabetes mellitus or chronic kidney disease. Most patients will require more than one agent to achieve these target blood pressures. Antihypertensive therapy should be considered in all adult patients regardless of age (caution should be exercised in elderly patients who are frail). For adults without compelling indications for other agents, initial therapy should include thiazide diuretics. Other agents appropriate for first-line therapy for diastolic and/or systolic hypertension include angiotensin- converting enzyme (ACE) inhibitors (in patients who are not black), long-acting calcium channel blockers (CCBs), angiotensin receptor antagonists (ARBs) or beta-blockers (in those younger than 60 years of age). A combination of two first-line agents may also be considered as the initial treatment of hypertension if the systolic blood pressure is 20 mmHg above the target or if the diastolic blood pressure is 10 mmHg above the target. The combination of ACE inhibitors and ARBs should not be used. Other agents appropriate for first-line therapy for isolated systolic hypertension include long- acting dihydropyridine CCBs or ARBs. In patients with angina, recent myocardial infarction or heart failure, beta-blockers and ACE inhibitors are recommended as first-line therapy; in patients with cerebrovascular disease, an ACE inhibitor/diuretic combination is preferred; in patients with proteinuric nondiabetic chronic kidney disease, ACE inhibitors or ARBs (if intolerant to ACE inhibitors) are recommended; and in patients with diabetes mellitus, ACE inhibitors or ARBs (or, in patients without albuminuria, thiazides or dihydropyridine CCBs) are appropriate first-line therapies. All hypertensive patients with dyslipidemia should be treated using the thresholds, targets and agents outlined in the Canadian Cardiovascular Society position statement (recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease). Selected high-risk patients with hypertension who do not achieve thresholds for statin therapy according to the position paper should nonetheless receive statin therapy. Once blood pressure is controlled, acetylsalicylic acid therapy should be considered.
All recommendations were graded according to strength of the evidence and voted on by the 57 members of the Canadian Hypertension Education Program Evidence-Based Recommendations Task Force. All recommendations reported here achieved at least 95% consensus. These guidelines will continue to be updated annually.
Notes
Cites: Circulation. 2000 Jun 6;101(22):2612-710840013
Cites: Lancet. 1999 Nov 20;354(9192):1751-610577635
Cites: JAMA. 2001 Jan 24-31;285(4):437-4311242428
Cites: Can J Cardiol. 2001 May;17(5):543-5911381277
Cites: Lancet. 2001 Sep 29;358(9287):1033-4111589932
Cites: N Engl J Med. 2001 Dec 6;345(23):1667-7511759645
Cites: Can J Cardiol. 2002 Jun;18(6):625-4112107420
Cites: Am J Med. 2002 Oct 1;113(5):359-6412401529
Cites: Lancet. 2003 Apr 5;361(9364):1149-5812686036
Cites: JAMA. 2003 May 21;289(19):2534-4412759325
Cites: J Am Coll Cardiol. 2003 Jun 18;41(12):2197-20412821247
Cites: Lancet. 2003 Sep 6;362(9386):767-7113678869
Cites: BMJ. 2004 Feb 7;328(7435):32614744823
Cites: Can J Cardiol. 2004 Jan;20(1):41-5414968142
Cites: Can J Cardiol. 2004 Jan;20(1):55-914968143
Cites: CMAJ. 1992 Jun 1;146(11):1997-20051596849
Cites: Am J Cardiol. 1998 Oct 16;82(8A):2N-9N9809895
Cites: Am J Kidney Dis. 1998 Nov;32(5 Suppl 3):S112-99820470
Cites: Lancet. 1999 Feb 20;353(9153):611-610030325
Cites: Lancet. 1999 Mar 6;353(9155):793-610459960
Cites: Ann Intern Med. 2004 Nov 16;141(10):781-815545678
Cites: BMC Cardiovasc Disord. 2005;5(1):415691376
Cites: J Am Coll Cardiol. 2005 Mar 1;45(5):712-915734615
Cites: Stroke. 2005 Jun;36(6):1218-2615879332
Cites: Can J Cardiol. 2005 Jun;21(8):657-7216003449
Cites: J Hypertens. 2005 Dec;23(12):2157-7216269957
Cites: Can J Cardiol. 2005 Dec;21(14):1265-7116341294
Cites: J Am Soc Nephrol. 2006 Mar;17(3 Suppl 1):S1-2716497879
Cites: J Cardiovasc Med (Hagerstown). 2006 Jan;7(1):29-3816645357
Cites: Can J Cardiol. 2006 May 15;22(7):559-6416755310
Cites: Can J Cardiol. 2006 May 15;22(7):583-9316755313
Cites: J Am Geriatr Soc. 2007 Mar;55(3):383-817341240
Cites: Lancet. 2007 Sep 8;370(9590):829-4017765963
Cites: Ann Intern Med. 2008 Jan 1;148(1):30-4817984482
Cites: Am J Ther. 2008 Jan-Feb;15(1):36-4318223352
Cites: Am J Hypertens. 2008 Feb;21(2):148-5218174885
Cites: J Hypertens. 2008 Mar;26(3):403-1118300848
Cites: J Hypertens. 2008 Apr;26(4):672-718327075
Cites: N Engl J Med. 2008 Apr 10;358(15):1547-5918378520
Cites: N Engl J Med. 2008 May 1;358(18):1887-9818378519
Cites: Lancet. 2008 May 10;371(9624):1575-618468534
Cites: Hypertension. 2008 Jun;51(6):1552-618391094
Cites: J Intern Med. 2008 Aug;264(2):187-9418393959
Cites: Lancet. 2008 Aug 16;372(9638):547-5318707986
Cites: N Engl J Med. 2008 Sep 18;359(12):1225-3718753639
Cites: Lancet. 2008 Sep 27;372(9644):1174-8318757085
Cites: Lancet. 2000 Dec 9;356(9246):1955-6411130523
PubMed ID
19417859 View in PubMed
Less detail

Attitudes to sharing personal health information in living kidney donation.

https://arctichealth.org/en/permalink/ahliterature144792
Source
Clin J Am Soc Nephrol. 2010 Apr;5(4):717-22
Publication Type
Article
Date
Apr-2010
Author
Patricia Hizo-Abes
Ann Young
Peter P Reese
Phil McFarlane
Linda Wright
Meaghan Cuerden
Amit X Garg
Author Affiliation
London Kidney Clinical Research Unit, Room ELL-101, Westminster, London Health Sciences Centre, 800 Commissioners Road East, London, Ontario N6A 4G5, Canada.
Source
Clin J Am Soc Nephrol. 2010 Apr;5(4):717-22
Date
Apr-2010
Language
English
Publication Type
Article
Keywords
Access to Information - legislation & jurisprudence
Adult
Aged
Attitude of Health Personnel
Confidentiality - legislation & jurisprudence - psychology
Cross-Sectional Studies
Female
Health Knowledge, Attitudes, Practice
Health Policy
Health Records, Personal
Humans
Informed Consent - legislation & jurisprudence - psychology
Kidney Transplantation - legislation & jurisprudence - psychology
Living Donors - legislation & jurisprudence - psychology
Male
Middle Aged
Ontario
Patient Education as Topic
Practice Guidelines as Topic
Questionnaires
Abstract
In living kidney donation, transplant professionals consider the rights of a living kidney donor and recipient to keep their personal health information confidential and the need to disclose this information to the other for informed consent. In incompatible kidney exchange, personal health information from multiple living donors and recipients may affect decision making and outcomes.
We conducted a survey to understand and compare the preferences of potential donors (n = 43), potential recipients (n = 73), and health professionals (n = 41) toward sharing personal health information (in total 157 individuals).
When considering traditional live-donor transplantation, donors and recipients generally agreed that a recipient's health information should be shared with the donor (86 and 80%, respectively) and that a donor's information should be shared with the recipient (97 and 89%, respectively). When considering incompatible kidney exchange, donors and recipients generally agreed that a recipient's information should be shared with all donors and recipients involved in the transplant (85 and 85%, respectively) and that a donor's information should also be shared with all involved (95 and 90%, respectively). These results were contrary to attitudes expressed by transplant professionals, who frequently disagreed about whether such information should be shared.
Future policies and practice could facilitate greater sharing of personal health information in living kidney donation. This requires a consideration of which information is relevant, how to put it in context, and a plan to obtain consent from all concerned.
Notes
Cites: Am J Transplant. 2003 Jul;3(7):830-412814474
Cites: Am J Transplant. 2009 Jul;9(7):1558-7319459792
Cites: Transplantation. 2004 Aug 27;78(4):491-215446304
Cites: Lancet. 1992 Oct 3;340(8823):807-101357243
Cites: Can J Surg. 2004 Dec;47(6):408-1315646438
Cites: Transplantation. 2005 Mar 27;79(6 Suppl):S53-6615785361
Cites: HIV Med. 2006 Apr;7(3):133-916494626
Cites: Ann Intern Med. 2006 Aug 1;145(3):185-9616880460
Cites: J Pers Assess. 2006 Dec;87(3):305-1617134338
Cites: Clin J Am Soc Nephrol. 2006 Nov;1(6):1148-5317699340
Cites: Am J Transplant. 2008 Sep;8(9):1878-9018671676
Cites: Nephrol Dial Transplant. 2008 Oct;23(10):3316-2418599559
Cites: N Engl J Med. 2009 Mar 12;360(11):1096-10119279341
Cites: J Med Ethics. 2009 Apr;35(4):270-119332587
Cites: Kidney Int. 2009 May;75(10):1088-9819225540
Cites: Am J Transplant. 2004 Oct;4(10):1553-415367208
PubMed ID
20299371 View in PubMed
Less detail

Canadian Society of Nephrology commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD.

https://arctichealth.org/en/permalink/ahliterature107111
Source
Am J Kidney Dis. 2013 Nov;62(5):860-73
Publication Type
Article
Date
Nov-2013
Author
Louise M Moist
Stéphan Troyanov
Colin T White
Lori D Wazny
Jo-Anne Wilson
Phil McFarlane
Lori Harwood
Manish M Sood
Steven D Soroka
Adam Bass
Braden J Manns
Author Affiliation
Department of Medicine and Epidemiology, Kidney Clinical Research Unit Western University, London, Ontario, Canada. Electronic address: louise.moist@lhsc.on.ca.
Source
Am J Kidney Dis. 2013 Nov;62(5):860-73
Date
Nov-2013
Language
English
Publication Type
Article
Keywords
Anemia - blood - etiology - therapy
Blood Transfusion
Canada
Evidence-Based Medicine
Hematinics - therapeutic use
Hemoglobins - metabolism
Humans
Iron - therapeutic use
Practice Guidelines as Topic
Quality of Life
Renal Dialysis - adverse effects
Renal Insufficiency, Chronic - therapy
Risk assessment
Abstract
The KDIGO (Kidney Disease: Improving Global Outcomes) 2012 clinical practice guideline for anemia management in patients with chronic kidney disease provides the structural and evidence base for the Canadian Society of Nephrology commentary on this guideline's relevancy and application to the Canadian health care system. While in general agreement, we provide commentary on 11 of the 61 KDIGO guideline statements. Specifically, we agreed that a therapeutic trial of iron is appropriate in cases in which a reduction in erythropoiesis-stimulating agent (ESA) dosage or avoidance of ESA and transfusion is desired, transferrin saturations are >30%, and ferritin concentrations are >500 µg/L. However, we concluded that there is insufficient evidence to support an upper target or threshold for ferritin and transferrin saturation levels. We agree with the initiation of ESA treatment when hemoglobin (Hb) level is 90-100 g/L; however, we specifically state that an acceptable range for Hb level is 95-115 g/L, with a target of 100-110 g/L, and add caution to individualization above this range due to concerns regarding the safety of ESAs. We agree that ESAs should be used with considerable caution in patients with active malignancy, history of stroke, or history of malignancy, and we suggest initiating ESA therapy at Hb level of 90 g/L and to aim for a Hb level in the range of 90-105 g/L. The reader is encouraged to note the level of evidence and review the entire KDIGO anemia guideline to interpret the guideline statements and commentary appropriately.
PubMed ID
24054466 View in PubMed
Less detail

Canadian Society of Nephrology commentary on the 2012 KDIGO clinical practice guideline for the management of blood pressure in CKD.

https://arctichealth.org/en/permalink/ahliterature104526
Source
Am J Kidney Dis. 2014 Jun;63(6):869-87
Publication Type
Article
Date
Jun-2014
Author
Marcel Ruzicka
Robert R Quinn
Phil McFarlane
Brenda Hemmelgarn
G V Ramesh Prasad
Janusz Feber
Gihad Nesrallah
Martin MacKinnon
Navdeep Tangri
Brendan McCormick
Sheldon Tobe
Tom D Blydt-Hansen
Swapnil Hiremath
Author Affiliation
Division of Nephrology, University of Ottawa, Ottawa, Ontario. Electronic address: mruzicka@ottawahospital.on.ca.
Source
Am J Kidney Dis. 2014 Jun;63(6):869-87
Date
Jun-2014
Language
English
Publication Type
Article
Keywords
Canada
Diabetic Nephropathies - physiopathology
Humans
Hypertension - complications - therapy
Life Style
Practice Guidelines as Topic
Randomized Controlled Trials as Topic
Renal Insufficiency, Chronic - complications - physiopathology
Societies, Medical
Sodium, Dietary - administration & dosage
Abstract
The KDIGO (Kidney Disease: Improving Global Outcomes) 2012 clinical practice guideline for the management of blood pressure (BP) in chronic kidney disease (CKD) provides the structural and evidence base for the Canadian Society of Nephrology (CSN) commentary on this guideline's relevancy and application to the Canadian health care system. While in general agreement, we provide commentary on 13 of the 21 KDIGO guideline statements. Specifically, we agreed that nonpharmacological interventions should play a significant role in the management of hypertension in patients with CKD. We also agreed that the approach to the management of hypertension in elderly patients with CKD should be individualized and take into account comorbid conditions to avoid adverse outcomes from excessive BP lowering. In contrast to KDIGO, the CSN Work Group believes there is insufficient evidence to target a lower BP for nondiabetic CKD patients based on the presence and severity of albuminuria. The CSN Work Group concurs with the Canadian Hypertension Education Program (CHEP) recommendation of a target BP for all non-dialysis-dependent CKD patients without diabetes of =140 mm Hg systolic and =90 mm Hg diastolic. Similarly, it is our position that in diabetic patients with CKD and normal urinary albumin excretion, raising the threshold for treatment from
PubMed ID
24725980 View in PubMed
Less detail

Prevalence estimates of chronic kidney disease in Canada: results of a nationally representative survey.

https://arctichealth.org/en/permalink/ahliterature114111
Source
CMAJ. 2013 Jun 11;185(9):E417-23
Publication Type
Article
Date
Jun-11-2013
Author
Paul Arora
Priya Vasa
Darren Brenner
Karl Iglar
Phil McFarlane
Howard Morrison
Alaa Badawi
Author Affiliation
Division of Science and Technology, Laboratory for Foodborne Zoonoses, Public Health Agency of Canada, Toronto, Ont.
Source
CMAJ. 2013 Jun 11;185(9):E417-23
Date
Jun-11-2013
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Age Factors
Aged
Albuminuria - epidemiology
Canada - epidemiology
Comorbidity
Creatinine - urine
Diabetes Mellitus - epidemiology
Female
Glomerular Filtration Rate
Health Surveys
Humans
Hypertension - epidemiology
Hypertriglyceridemia - epidemiology
Male
Middle Aged
Prevalence
Renal Insufficiency, Chronic - epidemiology
Risk factors
Sex Factors
Young Adult
Abstract
Chronic kidney disease is an important risk factor for death and cardiovascular-related morbidity, but estimates to date of its prevalence in Canada have generally been extrapolated from the prevalence of end-stage renal disease. We used direct measures of kidney function collected from a nationally representative survey population to estimate the prevalence of chronic kidney disease among Canadian adults.
We examined data for 3689 adult participants of cycle 1 of the Canadian Health Measures Survey (2007-2009) for the presence of chronic kidney disease. We also calculated the age-standardized prevalence of cardiovascular risk factors by chronic kidney disease group. We cross-tabulated the estimated glomerular filtration rate (eGFR) with albuminuria status.
The prevalence of chronic kidney disease during the period 2007-2009 was 12.5%, representing about 3 million Canadian adults. The estimated prevalence of stage 3-5 disease was 3.1% (0.73 million adults) and albuminuria 10.3% (2.4 million adults). The prevalence of diabetes, hypertension and hypertriglyceridemia were all significantly higher among adults with chronic kidney disease than among those without it. The prevalence of albuminuria was high, even among those whose eGFR was 90 mL/min per 1.73 m(2) or greater (10.1%) and those without diabetes or hypertension (9.3%). Awareness of kidney dysfunction among adults with stage 3-5 chronic kidney disease was low (12.0%).
The prevalence of kidney dysfunction was substantial in the survey population, including individuals without hypertension or diabetes, conditions most likely to prompt screening for kidney dysfunction. These findings highlight the potential for missed opportunities for early intervention and secondary prevention of chronic kidney disease.
Notes
Cites: Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-26611904577
Cites: JAMA. 2012 May 9;307(18):1941-5122570462
Cites: CMAJ. 2003 Jun 10;168(12):1553-6012796336
Cites: JAMA. 2004 Feb 18;291(7):844-5014970063
Cites: Adv Chronic Kidney Dis. 2006 Oct;13(4):352-6417045221
Cites: Arch Intern Med. 2007 Jul 9;167(13):1386-9217620532
Cites: JAMA. 2007 Nov 7;298(17):2038-4717986697
Cites: Health Rep. 2007;18 Suppl:7-2018210866
Cites: Health Rep. 2007;18 Suppl:31-618210868
Cites: Health Rep. 2007;18 Suppl:53-7018210870
Cites: BMC Public Health. 2008;8:11718405348
Cites: Lancet. 2008 Jun 28;371(9631):2173-8218586172
Cites: CMAJ. 2008 Nov 18;179(11):1154-6219015566
Cites: Ann Intern Med. 2009 May 5;150(9):604-1219414839
Cites: Can J Cardiol. 2009 May;25(5):271-719417857
Cites: Can J Cardiol. 2009 Oct;25(10):567-7919812802
Cites: JAMA. 2010 Feb 3;303(5):423-920124537
Cites: BMJ. 2010;341:c586921059726
Cites: CMAJ. 2011 Feb 8;183(2):E100-621149516
Cites: Kidney Int. 2011 Jun;79(12):1331-4021289598
Cites: Kidney Int. 2011 Jul;80(1):17-2821150873
Cites: CMAJ. 2011 Oct 18;183(15):E1127-3421911558
Cites: Lancet. 2012 Jan 14;379(9811):165-8021840587
Cites: Kidney Int. 2002 Jun;61(6):2165-7512028457
PubMed ID
23649413 View in PubMed
Less detail

6 records – page 1 of 1.